Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person midostaurin-resistant FLT3 mutants don't bind midostaurin

Class:IdFailedReaction:9702601
_displayNamemidostaurin-resistant FLT3 mutants don't bind midostaurin
_doReleaseTRUE
_timestamp2020-11-06 20:56:01
authored[InstanceEdit:9706566] Rothfels, Karen, 2020-11-06
compartment[Compartment:876] plasma membrane
created[InstanceEdit:9702599] Rothfels, Karen, 2020-10-01
disease[Disease:1500689] cancer
edited[InstanceEdit:9706566] Rothfels, Karen, 2020-11-06
entityFunctionalStatus[EntityFunctionalStatus:9702602] loss_of_function of midostaurin-resistant FLT3 mutants [plasma membrane]
input[DefinedSet:9699536] midostaurin-resistant FLT3 mutants [plasma membrane] [Homo sapiens]
[ChemicalDrug:2038921] midostaurin [cytosol]
isChimericFALSE
literatureReference[LiteratureReference:9702890] The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases
[LiteratureReference:9699345] Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
[LiteratureReference:9699384] The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
[LiteratureReference:9699239] Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
[LiteratureReference:9699271] Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia
modified[InstanceEdit:9702941] Rothfels, Karen, 2020-10-02
[InstanceEdit:9703541] Rothfels, Karen, 2020-10-06
[InstanceEdit:9704328] Rothfels, Karen, 2020-10-07
[InstanceEdit:9706570] Rothfels, Karen, 2020-11-06
[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
namemidostaurin-resistant FLT3 mutants don't bind midostaurin
normalReaction
releaseDate2020-12-08
reviewed[InstanceEdit:9706568] Kazi, Julhash U, 2020-11-06
reviewStatus[ReviewStatus:9821382] five stars
species[Species:48887] Homo sapiens
stableIdentifier[StableIdentifier:9702603] R-HSA-9702601.2
summation[Summation:9702925] The following FLT3 mutants are resistant to inhibition by th...
(hasEvent)[Pathway:9702600] midostaurin-resistant FLT3 mutants [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by midostaurin-resistant FLT3 mutants don't bind midostaurin (9702601)
Follow Reactome